Scancell Holdings plc (SCLP.L), a clinical-stage biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration (FDA) had granted a fast track designation to iSCIB1+ for the treatment of advanced melanoma. It also provided updates on the Phase 2 SCOPE trial.
The company's lead drug iSCIB1+ was developed on the DNA ImmunoBody platform to treat advanced unresectable melanoma. The treatment delivery is through the PharmaJet needle-free injection.
The Phase 2 trial is a multicenter, open-label study evaluating SCIB1 or iSCB1+, administered in up to 11 doses with a standard-of-care therapy like Nivolumab plus Ipilimumab, or Pembrolizumab. Safety and efficacy of the drug will be measured using endpoints like disease control rate (DCR), duration of response (DOR), progression free survival (PFS) and overall survival (OS). Scancell reported a PFS of 77% at 20 months in the target population treated with the drug, a 30% increase from the 43% PFS of the placebo cohort.
Additional PFS and OS data from the Phase 2 SCOPE trial is expected by the first half of 2027.
SCLP.L is currently trading at £13.50, up 3.85%
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.